The anticancer effect of MAGL inhibition in prostate cancer was totally abolished by cotreatment with SR141716 (rimonabant; CB1 receptor antagonist) and fatty acids, signifying that amplified endocannabinoid action and reduced stock of FFA from MAGL inhibition is the reason behind antitumor effect [26]. Here, MGLL is linked to prostate cancer.